Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
MBAI stock price ended at $1.82 on 星期四, after dropping 1.62%
On the latest trading day Feb 12, 2026, the stock price of MBAI fell by 1.62%, dropping from $1.85 to $1.82. During the session, the stock saw a volatility of 8.14%, with prices oscillating between a daily low of $1.72 and a high of $1.86. On the latest trading day, the trading volume for MBAI decreased by 35.1K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 30.0K shares were traded, with a market value of approximately $12.7M.